Monthly News Roundup - September 2020

Genentech’s Gavreto Cleared for RET Fusion-Positive NSCLC Gavreto (pralsetinib) is a RET kinase inhibitor used for the treatment of adults with metastatic rearranged during transfection (RET) fusion positive non-small cell lung cancer...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news